Taysha Gene Therapies Total Assets 2020-2024 | TSHA
Taysha Gene Therapies total assets from 2020 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Taysha Gene Therapies Annual Total Assets
(Millions of US $) |
| 2023 |
$173 |
| 2022 |
$126 |
| 2021 |
$214 |
| 2020 |
$259 |
| 2019 |
$0 |
Taysha Gene Therapies Quarterly Total Assets
(Millions of US $) |
| 2024-06-30 |
$200 |
| 2024-03-31 |
$153 |
| 2023-12-31 |
$173 |
| 2023-09-30 |
$196 |
| 2023-06-30 |
$82 |
| 2023-03-31 |
$102 |
| 2022-12-31 |
$126 |
| 2022-09-30 |
$111 |
| 2022-06-30 |
$142 |
| 2022-03-31 |
$166 |
| 2021-12-31 |
$214 |
| 2021-09-30 |
$241 |
| 2021-06-30 |
$242 |
| 2021-03-31 |
$243 |
| 2020-12-31 |
$259 |
| 2020-09-30 |
$279 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.314B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
